Medicare Enrolled
Dr. John Khoury, MD
Hematology & Oncology · Cerritos, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khoury from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khoury?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khoury
Dr. John Khoury is a hematology & oncology specialist in Cerritos, CA, with 11 years of NPI registration. Based on federal Medicare data, Dr. Khoury performed 1,583 Medicare services across 248 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khoury received a total of $58,565 from 87 pharmaceutical and/or device companies across 871 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khoury is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ Top 43% volume in CA
$58,565 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,583
Medicare services
Top 43% in CA for hematology & oncology
248
Unique beneficiaries
$26
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~144 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 560 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
490 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
156 | $91 | $274 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
94 | $121 | $304 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
66 | $93 | $140 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
56 | $25 | $68 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
49 | $69 | $195 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
33 | $22 | $63 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
23 | $33 | $123 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
20 | $59 | $147 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
18 | $7 | $13 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
18 | $134 | $374 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.7% high complexity
66.3% medium
22.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$58,565
Total received (2018-2024)
Avg $8,366/year across 7 years
Top 11% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
87
Companies
871
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$31,654 (54.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,599 (30.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,312 (15.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,052
2023
$18,818
2022
$29,762
2021
$5,090
2020
$1,808
2019
$653
2018
$382
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$155
PFIZER INC.
$142
Merck Sharp & Dohme LLC
$129
Novartis Pharmaceuticals Corporation
$116
Incyte Corporation
$102
GlaxoSmithKline, LLC.
$98
Eisai Inc.
$97
AstraZeneca Pharmaceuticals LP
$91
Bausch & Lomb Americas Inc.
$91
Astellas Pharma US Inc
$78
EMD Serono, Inc.
$68
Exelixis Inc.
$60
E.R. Squibb & Sons, L.L.C.
$59
Karyopharm Therapeutics Inc.
$53
Takeda Pharmaceuticals U.S.A., Inc.
$51
Bayer Healthcare Pharmaceuticals Inc.
$51
Celgene Corporation
$50
Daiichi Sankyo Inc.
$47
Janssen Biotech, Inc.
$45
ABIOMED
$40
Lilly USA, LLC
$40
Regeneron Healthcare Solutions, Inc.
$35
SUN PHARMACEUTICAL INDUSTRIES INC.
$33
PharmaEssentia USA Corporation
$33
Genmab U.S., Inc.
$32
Gilead Sciences, Inc.
$31
ARRAY BIOPHARMA INC
$31
Genentech USA, Inc.
$29
Novocure Inc.
$29
Agios Pharmaceuticals, Inc.
$28
BeiGene USA, Inc.
$25
ImmunoGen, Inc.
$24
Alexion Pharmaceuticals, Inc.
$23
SOBI, INC
$19
Stemline Therapeutics Inc.
$16
Top 3 companies account for 20.8% of 2024 payments
All-time payments by company (2018-2024) ›
Pharmacyclics LLC, an AbbVie Company
$15,409
Pharmacyclics LLC, An AbbVie Company
$6,912
Janssen Biotech, Inc.
$6,602
AstraZeneca Pharmaceuticals LP
$4,392
Novartis Pharmaceuticals Corporation
$3,576
PFIZER INC.
$3,501
Karyopharm Therapeutics Inc.
$3,138
Incyte Corporation
$1,081
Lilly USA, LLC
$888
E.R. Squibb & Sons, L.L.C.
$867
Celgene Corporation
$817
GlaxoSmithKline, LLC.
$762
Amgen Inc.
$744
Seagen Inc.
$673
Eisai Inc.
$594
Astellas Pharma US Inc
$527
Bayer HealthCare Pharmaceuticals Inc.
$459
Merck Sharp & Dohme LLC
$442
Takeda Pharmaceuticals U.S.A., Inc.
$387
Alexion Pharmaceuticals, Inc.
$367
GENZYME CORPORATION
$331
Exelixis Inc.
$298
ABBVIE INC.
$270
Bayer Healthcare Pharmaceuticals Inc.
$262
Gilead Sciences, Inc.
$260
Daiichi Sankyo Inc.
$250
Kite Pharma, Inc.
$246
Merck Sharp & Dohme Corporation
$239
Bausch & Lomb Americas Inc.
$210
Myovant Sciences Inc.
$205
Blueprint Medicines Corporation
$188
ARRAY BIOPHARMA INC
$178
Genentech USA, Inc.
$177
Boehringer Ingelheim Pharmaceuticals, Inc.
$162
GE HealthCare
$151
Sumitomo Pharma America, Inc.
$145
EMD Serono, Inc.
$133
Dova Pharmaceuticals
$119
Ipsen Biopharmaceuticals, Inc
$119
TOLMAR Pharmaceuticals, Inc.
$114
SK Life Science, Inc.
$113
PUMA BIOTECHNOLOGY, INC.
$107
Rigel Pharmaceuticals, Inc.
$107
Global Blood Therapeutics, Inc.
$104
PharmaEssentia USA Corporation
$99
EUSA Pharma (US) LLC
$96
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$92
JAZZ PHARMACEUTICALS INC.
$91
Stemline Therapeutics Inc.
$71
EISAI INC.
$68
TerSera Therapeutics LLC
$67
SOBI, INC
$66
Puma Biotechnology, Inc.
$60
BeiGene USA, Inc.
$59
Regeneron Healthcare Solutions, Inc.
$59
Genmab U.S., Inc.
$58
Adaptive Biotechnologies Corporation
$57
Agios Pharmaceuticals, Inc.
$57
Blue Earth Diagnostics Limited
$52
Novocure Inc.
$50
Mirati Therapeutics, Inc.
$49
Sobi, Inc
$49
MorphoSys, US Inc.
$47
Secura Bio, Inc.
$45
ImmunoGen, Inc.
$43
Epizyme, Inc.,
$43
Sun Pharmaceutical Industries Inc.
$42
ABIOMED
$40
Taiho Oncology, Inc.
$40
GE HEALTHCARE
$38
Myriad Genetic Laboratories, Inc.
$38
Organon LLC
$36
Deciphera Pharmaceuticals Inc.
$35
SUN PHARMACEUTICAL INDUSTRIES INC.
$33
Dendreon Pharmaceuticals LLC
$31
ADC Therapeutics America, Inc.
$28
AVEO Pharmaceuticals, Inc.
$26
AMAG Pharmaceuticals, Inc.
$24
RECORDATI_RARE_DISEASES_INC.
$20
Aurobindo Pharma USA, Inc.
$19
TAIHO ONCOLOGY, INC.
$18
Progenics Pharmaceuticals, Inc.
$18
MACROGENICS, INC.
$18
SECURA BIO, INC.
$15
Tolmar, Inc.
$14
Novo Nordisk Inc
$14
Apellis Pharmaceuticals, Inc.
$12
Top 3 companies account for 49.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AYVAKIT · Axumin · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · CERDELGA · COPIKTRA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · Elahere · Empaveli · Enhertu · Epkinly · FARYDAK · FERAHEME · FOTIVDA · FRUZAQLA · Fabhalta · Folotyn · GAVRETO · GILOTRIF · GLEEVEC · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Impella · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · LifeVest · MARGENZA · MEKINIST · MONJUVI · NERLYNX · NEXPLANON · NINLARO · Natazia · Nerlynx · Neulasta · NovoSeven RT · Nplate · Nubeqa · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · ORGOVYX · OXBRYTA · Optune · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Padcev · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · Revlimid · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Stivarga · Sylvant · TABRECTA · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · Vectibix · Venclexta · XCOPRI · XOSPATA · XPOVIO · XTANDI · XYWAV · Xermelo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ · enVista MX60 IOL · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (54%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Hematology & oncology specialists within 10 mi
383
Per 100K population
3.9
County median income
$87,760
Nearest hospital
COLLEGE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Khoury is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 11% of CA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Khoury experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Khoury performed 560 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khoury receive payments from pharmaceutical companies?
Yes. Dr. Khoury received a total of $58,565 from 87 companies across 871 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khoury's costs compare to other hematology & oncology specialists in Cerritos?
Dr. Khoury's average Medicare payment per service is $26. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khoury) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Cerritos
Browse hematology & oncology specialists in Cerritos ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Pharmacyclics LLC, an AbbVie Company Payments to Doctors
See all physicians who received payments from Pharmacyclics LLC, an AbbVie Company.
By company
Pharmacyclics LLC, An AbbVie Company Payments to Doctors
See all physicians who received payments from Pharmacyclics LLC, An AbbVie Company.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology